the vasodilatory action , plasma papaverine levels achieved , and the incidence of side effects after oral administration of papaverine hydrochloride as a soft gelatin capsule , were compared to those of a sustained release formulation .
C0030350
papaverine
C0700461
papaverine hydrochloride